Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant

18740

Stereotactic body radiation therapy (sbrt) in the treatment of liver tumors
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT00691691
Liver malignancy
Stereotactic Body Radiation Therapy
Efficacy of SBRT in liver tumors
Hepatic toxicity with SBRT
Source : Importé depuis le centre
Liver Tumors
Recrutement possiblement ouvert
Dernière modification : 2012/01/17
Type de recherche

Interventionnel

Médicament expérimental

PHASE2


Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Liver Tumors

Source : Importé depuis le centre

Profil des participants

Donnée non disponible

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* Histologically conformation of liver malignancy
* Solitary or multiple liver tumors amenable to SBRT
* No jaundice or liver dysfunction
* For metastases, the primary tumor site has been adequately treated.
* For primary hepatoma, no extra-hepatic disease
* Karnofsky \> 70

Exclusion Criteria:

* no extra-hepatic disease
* Liver failure or inadequate liver function
* Ascites
* Previous radiation therapy to the liver
* lesions invading major blood vessels in the porta region
* Contraindication to receive radiation therapy in the liver

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
1 Donnée non disponible Eligible patient will be treated with 48 Gy in 4 fractions encompassing the entire target lesion in 2 weeks with a minimum of 48 hours between each dose.
  • Inconnu
  • 1
    État du recrutement
    unknown
    Données à jour depuis : 17 janvier 2012

    Description de l'étude

    Résumé de l'étude

    Patients with primary hepato-biliary malignancies or liver metastases from gastrointestinal cancer suffer substantial morbidity and mortality from their hepatic disease. Curative resection is feasible only for selected subgroups of patients. The majority of patients have unresectable and incurable disease. Aggressive arterial and systemic chemotherapy have been used in recent years with improved response and survival. However, a significant number of patients, at least one-third of patients with liver metastases from colorectal cancer and two-third or higher of unresectable hepatobiliary cancer, continue to die of liver failure from progressive disease in the liver. Percutaneous ethanol injections, chemoembolization, cryotherapy and thermal ablation using radiofrequency have been used to treat selected patients with smaller tumors (3-4 cm) in areas away from major blood vessels and the biliary tract. However, most unresectable liver cancers did not fit the criteria for these treatments. Therefore, other regional therapeutic option like external radiation therapy may be considered for local control in the liver or symptom palliation

    Source : Importé depuis le centre

    Sites

    Centres participants


    Dernière modification : 17 janvier 2012
    Données à jour depuis : 22 mars
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT00691691